Bridget E. Bunner

Array ( [id] => 11324991 [patent_doc_number] => 20160355603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-08 [patent_title] => 'Methods and Compositions for the Treatment of Pancreatic Cancer' [patent_app_type] => utility [patent_app_number] => 15/244833 [patent_app_country] => US [patent_app_date] => 2016-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 17684 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15244833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11491507 [patent_doc_number] => 20170065692 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-09 [patent_title] => 'USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER' [patent_app_type] => utility [patent_app_number] => 15/241757 [patent_app_country] => US [patent_app_date] => 2016-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 44 [patent_no_of_words] => 16506 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15241757 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11436111 [patent_doc_number] => 20170037130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'ANTIBODY CONSTRUCTS FOR DLL3 AND CD3' [patent_app_type] => utility [patent_app_number] => 15/225107 [patent_app_country] => US [patent_app_date] => 2016-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 53775 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15225107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393992 [patent_doc_number] => 20170014526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'ANTI-NOTCH3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/221049 [patent_app_country] => US [patent_app_date] => 2016-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 33663 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15221049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12837478 [patent_doc_number] => 20180170999 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => BTLA FUSION PROTEIN AGONISTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/737259 [patent_app_country] => US [patent_app_date] => 2016-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15334 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15737259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14230523 [patent_doc_number] => 20190127434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => METHOD FOR PRODUCING TLR5 AGONIST PROTEIN [patent_app_type] => utility [patent_app_number] => 15/553191 [patent_app_country] => US [patent_app_date] => 2016-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3952 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15553191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11618340 [patent_doc_number] => 20170128526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'STEM CELL DERIVED FACTORS FOR TREATING PATHOLOGIC CONDITIONS' [patent_app_type] => utility [patent_app_number] => 15/167058 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 16530 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15167058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11120640 [patent_doc_number] => 20160317615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'T CELL MODULATOR' [patent_app_type] => utility [patent_app_number] => 15/144680 [patent_app_country] => US [patent_app_date] => 2016-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 10246 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15144680 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16128435 [patent_doc_number] => 10697970 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-30 [patent_title] => S100A9 levels for predicting lenalidomide and erythropoietin responsiveness [patent_app_type] => utility [patent_app_number] => 15/570916 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 67 [patent_figures_cnt] => 124 [patent_no_of_words] => 16228 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15570916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15165851 [patent_doc_number] => 10488411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-26 [patent_title] => Inflammasome activation in myelodysplastic syndromes [patent_app_type] => utility [patent_app_number] => 15/570019 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 112 [patent_no_of_words] => 14782 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15570019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11393942 [patent_doc_number] => 20170014477 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'FREE RAPTOR REDUCES AGING- AND OBESITY-INDUCED FATTY LIVER' [patent_app_type] => utility [patent_app_number] => 15/143305 [patent_app_country] => US [patent_app_date] => 2016-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 78 [patent_figures_cnt] => 78 [patent_no_of_words] => 28979 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15143305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11082288 [patent_doc_number] => 20160279253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-29 [patent_title] => 'N-TERMINAL MODIFIED PEG-TRAIL' [patent_app_type] => utility [patent_app_number] => 15/138109 [patent_app_country] => US [patent_app_date] => 2016-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13009 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15138109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11025175 [patent_doc_number] => 20160222130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-08-04 [patent_title] => 'NOVEL ANTI-HUMAN TIE-2 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/134803 [patent_app_country] => US [patent_app_date] => 2016-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 26047 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15134803 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11343526 [patent_doc_number] => 09527921 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-27 [patent_title] => 'Anti human Notch4 antibody' [patent_app_type] => utility [patent_app_number] => 15/098869 [patent_app_country] => US [patent_app_date] => 2016-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 12 [patent_no_of_words] => 16970 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15098869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12675859 [patent_doc_number] => 20180117119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => AGENT FOR INDUCING AMPLIFICATION OF HEMATOPOIETIC STEM CELLS [patent_app_type] => utility [patent_app_number] => 15/565862 [patent_app_country] => US [patent_app_date] => 2016-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15565862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11469715 [patent_doc_number] => 20170056498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS' [patent_app_type] => utility [patent_app_number] => 15/095393 [patent_app_country] => US [patent_app_date] => 2016-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13730 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15095393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16459520 [patent_doc_number] => 10842848 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Method for treating cancer by adminstering poly I:C and LAG-3-IgG fusion protein [patent_app_type] => utility [patent_app_number] => 15/564604 [patent_app_country] => US [patent_app_date] => 2016-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 29 [patent_no_of_words] => 8756 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15564604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11100915 [patent_doc_number] => 20160297884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-13 [patent_title] => 'CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN' [patent_app_type] => utility [patent_app_number] => 15/085317 [patent_app_country] => US [patent_app_date] => 2016-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 51406 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15085317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12706993 [patent_doc_number] => 20180127497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-10 [patent_title] => USE OF KIT INHIBITORS TO CONDITION SUBJECTS FOR A HEMATOPOIETIC STEM CELL (HSC) TRANSPLANTATION [patent_app_type] => utility [patent_app_number] => 15/561126 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15561126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12724384 [patent_doc_number] => 20180133295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => A Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist [patent_app_type] => utility [patent_app_number] => 15/557647 [patent_app_country] => US [patent_app_date] => 2016-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15557647 [rel_patent_id] =>[rel_patent_doc_number] =>)